e-learning
resources
Vienna 2009
Monday, 14.09.2009
New bronchodilators
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study
R. Buhl, W. Pieters, D. Jack, R. Owen, B. Kramer, M. Higgins (Mainz, Germany; Helmond, Netherlands; Horsham, United Kingdom; East Hanover, United States Of America)
Source:
Annual Congress 2009 - New bronchodilators
Session:
New bronchodilators
Session type:
Thematic Poster Session
Number:
2026
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Buhl, W. Pieters, D. Jack, R. Owen, B. Kramer, M. Higgins (Mainz, Germany; Helmond, Netherlands; Horsham, United Kingdom; East Hanover, United States Of America). Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study. Eur Respir J 2009; 34: Suppl. 53, 2026
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study
versus
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Once-daily QVA149 improves symptom scores in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study
Source: Eur Respir J 2014; 43: 1599-1609
Year: 2014
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation
vs
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 26s
Year: 2001
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Source: Eur Respir J 2011; 38: 797-803
Year: 2011
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
LATE-BREAKING ABSTRACT: Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept